LLS Phone Education Programs for November: "Understanding AML"

On November 24 2009, as part of the Leukemia & Lymphoma Society's ongoing Lymphoma Education Series, the LLS is offering another FREE telephone education program.

In order to participate, you need only to register. These are free, 90 minute teleconferences/webcasts hosted by blood cancer experts and followed by sessions in which you can ask questions. You don't need to go anywhere to participate, you don't need to pay anything, you just need to call in at the proper time.

Program: Understanding Acute Myelogenous Leukemia (AML): From Diagnosis To Treatment

Hosted by: Elihu H. Estey, MD
Professor of Medicine, Division of Hematology
University of Washington School of Medicine
Member, Fred Hutchinson Cancer Research Center
Seattle, WA
Adjunct Professor, The University of Texas
M.D. Anderson Cancer Center
Houston, TX

Learn more about:
-- Blood and marrow tests used to diagnose AML
-- Current and emerging treatment options for AML
-- Treatment side effects and strategies for side effect management
-- Potential benefits to patients participating in clinical trials

Click HERE for the program's main information page, and to access the registration page.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap